MRSA Drugs Market Research Report Information by Drug Class (Sulfa Drugs, Tetracyclines, Oxazolidinones, Folate Antagonists, Lipopeptide, Glycopeptide Antibiotics and others), MRSA Types (Hospital-Acquired (HA-MRSA) and Community-Acquired (CA-MRSA)), Disease Indication (Skin Infections, Bone and Joint Infections and Bacteremia and Animal Infections) End User (Hospitals and Clinics, Research and Academic Institutes) - Forecast till 2030

MRSA Drugs Market Overview

The MRSA Drugs Market is projected to reach USD 4130.46 Million by 2030 at 4.4% CAGR during the forecast period 2022-2030. Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen. This infection is generally associated with invasive procedures such as surgeries, intravenous tubing, and sometimes through the skin to skin contact. MRSA drugs are used to kill or restrain methicillin-resistant staphylococcus aureus infection.

The increase in the prevalence of MRSA infections and number of hospitals, growing awareness about a bacterial infection, and increase in immuno-compromised population are expected to enhance the market growth. However, the high cost of novel MRSA drugs and hospital readmissions reduction program is projected to curb the growth of the market.

Market Dynamics

MRSA drugs have been gaining significant growth in recent years owing to the rising awareness about MRSA infections. For instance, October is celebrated as world MRSA awareness month and November 18, is celebrated as antibiotic awareness day in Europe to raise awareness of antibiotic resistance and promote the judicious use of antibiotics. Thus, the growing awareness about the cause and treatment related to bacterial infection among the population led to an increased usage of MRSA drug market, which thereby provides a favorable scenario for the market to grow during the forecast period.

MRSA Drugs Market Share, by MRSA Type, 2016 & 2023  

Source: MRFR Analysis

Segmentation

The MRSA drugs market, by drug class, has been segmented into sulfa drugs, tetracyclines, oxazolidinones, folate antagonists, lipopeptide, glycopeptide antibiotics, and others. Based on MRSA types, the MRSA drugs market has been categorized as hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA). By disease indication, the market is divided into skin infections, bone and joint infections, and bacteremia, and animal infections. Based on end user, the MRSA Drugs market has been categorized as hospitals and clinics, research and academic institutes, and others.

North America MRSA Drugs Market Share, 2016 (%)  

Source: MRFR Analysis

Regional Analysis

The MRSA drugs market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is expected to hold the largest share of the MRSA drugs market. This is owing to the presence of key market players, well-developed healthcare infrastructure, in the US and Canada. Canada held 25% in North America MRSA Drugs market in 2016.

Europe holds the second position in MRSA drugs market due to the increasing research & development in the healthcare industry, availability of funds for research, rising cases of bacterial infection, and increasing adoption of novel drugs for the treatment of MRSA.

Asia-Pacific is projected to be the fastest-growing region in the global market due to the rapidly developing medical industry, the presence of a huge patient pool, and increasing expenditure in healthcare by the government. China held a share of 25.1% in the Asia-Pacific MRSA drugs market in 2016. The Middle East & Africa holds the least market share in the MRSA drugs market.

Key Players

The prominent players in the MRSA drugs market are Merck KGaA (UK), Olon (Italy), Allergan (Dublin, Ireland), Baxter (US), Theravance Biopharma (Theravance Biopharma), Pfizer (US), Mylan NV (US), and Novartis (Switzerland).

Some of the key strategies followed by players operating in the MRSA drugs market were innovation, product development, and acquisition & mergers.

• Americas showed high demand for the high-end MRSA drugs products due to broader market size and higher spending power.


• China is expected to be one of the top three fastest-growing markets for MRSA drugs shortly.


• Merck KGaA and Pfizer PLC are some of the prominent market players in the MRSA drugs market.

Market Segmentation

MRSA Drugs Market, by Drug Class

• Sulfa Drugs


• Tetracyclines


• Oxazolidinones


• Folate Antagonists


• Lipopeptide


• Glycopeptide Antibiotics


• Others

MRSA Drugs Market, by MRSA Type

• Hospital-Acquired (HA-MRSA)


• Community-Acquired (CA-MRSA)

MRSA Drugs Market, by Disease Indication

• Skin Infections


• Bone and Joint Infections


• Bacteremia


• Animal Infections

MRSA Drugs Market, by End User

• Hospitals and Clinics


• Research and Academic Institutes


• Others

MRSA Drugs Market, by Region

• Americas
  
  
  
  • North America
    
    
    
    • US
    
    
    • Canada
    
    
    
    
  
  
  • Latin America
  
  
  
  

• Europe
  
  
  
  • Western Europe
    
    
    
    • Germany
    
    
    • UK
    
    
    • France
    
    
    • Italy
    
    
    • Spain
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  • Eastern Europe
  
  
  
  

• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  

• Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa
  
  
  
  

Available Additional Customizations

• 
  Company Profiles of Other Key Players
  
  
  
  • The Medicines Company
  
  
  • Basilea Pharmaceutica Ltd
  
  
  • Cellceutix
  
  
  • Cempra
  
  
  • CrystalGenomics
  
  
  • Debiopharm
  
  
  • Galapagos
  
  
  • GSK
  
  
  
  


• MRSA Drugs Market, Industry Trends

Intended Audience

• Pharmaceutical companies


• 
  Contract research manufacturing organizations


• Research & development organizations


• Academic institutes